Recently Approved Alzheimer Drug Raises Questions That Might Never Be Answered

The Food and Drug Administration’s (FDA’s) approval June 7 of the drug aducanumab was notable for a number of reasons:

Neurologist Allan Levey, MD, PhD, director of Emory University’s Goizueta Alzheimer Disease Research Center, was blunt in his assessment of aducanumab, sold under the brand name Aduhelm and marketed by Biogen, based in Cambridge, Massachusetts, and Eisai, headquartered in Tokyo.